Document Detail

Thrombolytic therapy in acute myocardial infarction.
MedLine Citation:
PMID:  10874525     Owner:  NLM     Status:  MEDLINE    
Early reperfusion of thrombotically occluded coronary arteries by thrombolytic therapy has become a routine option in initial therapy of acute myocardial infarction. Many efforts have been made to improve the biological properties of thrombolytic agents in terms of fibrin specificity, plasma half-life and resistance to natural plasma inhibitors, to improve adjuvant therapy and to shorten the 'pain to reperfusion' time. Numerous randomised, multicentre trials have analysed the benefit of the various thrombolytic agents and regimens, which has enabled the creation of a 'current standard of therapy'. This review presents an update on available thrombolytic agents, their biochemical and pharmacological properties and results from clinical trials.
U Priglinger; K Huber
Related Documents :
12925455 - Effect of pexelizumab, an anti-c5 complement antibody, as adjunctive therapy to fibrino...
11519775 - Tenecteplase: a review.
22562745 - Left atrial remodelling in competitive adolescent soccer players.
2495745 - The thrombolytic effects of native tissue-type plasminogen activator (ak-124) on experi...
18231905 - Troponin in hematologic oncology.
2684145 - Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  16     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-09-13     Completed Date:  2000-10-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  301-12     Citation Subset:  IM    
Department of Cardiology, University of Vienna Medical School, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Pharmaceutic / therapeutic use*
Age Factors
Drug Therapy, Combination
Fibrinolytic Agents / contraindications,  pharmacology,  therapeutic use*
Middle Aged
Multicenter Studies as Topic
Myocardial Infarction / drug therapy*
Randomized Controlled Trials as Topic
Risk Factors
Reg. No./Substance:
0/Adjuvants, Pharmaceutic; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfun...
Next Document:  Subcutaneous hydration by hypodermoclysis. A practical and low cost treatment for elderly patients.